Key result
In most experimental models of hypertension or renal failure, AT1 receptor antagonists and ACE inhibitors demonstrated similar antihypertensive and renoprotective profiles.
Why the study?
Do AT1 receptor antagonists and ACE inhibitors have similar renoprotective and antihypertensive effects in experimental models of hypertension or renal failure?
Do AT1 receptor antagonists and ACE inhibitors have similar renoprotective and antihypertensive effects in experimental models of hypertension or renal failure?
This review suggests that while AT1 antagonists and ACE inhibitors generally have similar renoprotective and antihypertensive effects in experimental models, ACE inhibitors may offer additional benefits in some models due to non-AT1-mediated mechanisms.
No takes yet. Share an insight, caveat, or question.
May support ARB–ACEI equivalence in most experimental hypertension models; leaves open non-AT1 advantages in select settings.
Jover et al. (2000) conducted a review in Experimental renal diseases and hypertension. Angiotensin II type 1 receptor (AT1) antagonists vs. Angiotensin-converting enzyme (ACE) inhibitors was evaluated on Antihypertensive and renal profiles. In most experimental models of hypertension or renal failure, AT1 receptor antagonists and ACE inhibitors demonstrated similar antihypertensive and renoprotective profiles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: